share_log

Unveiling 26 Analyst Insights On Sarepta Therapeutics

Benzinga ·  Sep 6 13:01

Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 26 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings317600
Last 30D01000
1M Ago05200
2M Ago01000
3M Ago310400

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $188.31, a high estimate of $235.00, and a low estimate of $128.00. This current average reflects an increase of 7.65% from the previous average price target of $174.92.

1725642101_0.png

Deciphering Analyst Ratings: An In-Depth Analysis

The perception of Sarepta Therapeutics by financial experts is analyzed through...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment